Skip to main content
Pharmafile

Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?

Autumn 2019
Authors
Maria Isabel ManleyDr. Chris Boyle

Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.

View Article

Contacts

Manley, Maria Isabel
パートナー
Boyle, Chris
パートナー

Capabilities

Suggested News & Insights

Sidley Advises Verdane in Its Partnership With SmartboxMarch 12, 2026
Announcements
New U.S. FDA Letter Contradicts Decades-Old Precedent on Prescription Drug PromotionMarch 10, 2026
Global Life Sciences Update
Animal Health, Nutrition & Technology Innovation – Shaping the Future of Animal HealthMonday, March 2, 2026 - Tuesday, March 3, 2026
Events
Sidley Represents Precision NeuroMed in Its Strategic Partnership With Brainlab SEFebruary 27, 2026
Announcements
Veterinary Biologics and Biosimilars: Routes to Approval and Commercialization in the U.S., EU, and UKFebruary 20, 2026
Animal Health Update
Drug Pricing and Medicaid Rebate Reporting: Enforcement Risk RemainsFebruary 17, 2026
Reuters